Open access · CC-BY
via OpenAlex
METFORMIN AS A POTENTIAL PHARMACOLOGIC INTERVENTION TO IMPROVE HEALTHSPAN
Innovation in Aging · 2024
Epigenetic alterations
Dysbiosis
Deregulated nutrient-sensing
Mitochondrial dysfunction
Cellular senescence
Metformin
Human
Preclinical / animal
Abstract
Abstract Metformin is the most widely used oral antidiabetic drug, generally recommended as first-line treatment for type 2 diabetes as well as for diabetes prevention. Metformin extends lifespan in preclinical models, and several observational studies in humans suggest that metformin reduces cancer, cardiovascular disease, dementia, frailty, and all-cause mortality. Therefore, given that it is well-tolerated, safe, and widely used, there is high interest in testing its role as a potential agent to reduce age-related diseases and geriatric syndromes. The exact mechanisms by which metformin exerts these benefits are still being elucidated, but in addition to activating AMPK emerging evidence demonstrates metformin modulates several telomere(definition) attrition, cellular senescence(definition))." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">hallmarks of aging(definition), such as epigenetic modifications, mitochondrial function, cellular senescence and the gut microbiome. Thus, metformin has pleiotropic effects which may contribute, perhaps collectively, to its aging-modulating properties. To date there are few clinical trials of metformin to directly examine metformin’s effects on human healthspan(definition). We are currently conducting a randomized placebo-controlled clinical trial of metformin to prevent frailty in older adults with glucose intolerance, which will also examine the effects of metformin on several hallmarks of aging. Metformin is also being examined in a separate ongoing randomized placebo-controlled trial as a potential therapy to prevent Alzheimer’s disease in older adults without diabetes (including those who have prediabetes). Given its tolerability and safety profile, metformin could be quickly translated to clinical use if ongoing and future clinical trials demonstrate its efficacy in promoting healthspan.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/geroni/igae098.0450
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Espinoza, S.E. (2024). METFORMIN AS A POTENTIAL PHARMACOLOGIC INTERVENTION TO IMPROVE HEALTHSPAN. <em>Innovation in Aging</em>. https://doi.org/10.1093/geroni/igae098.0450
Vancouver
Espinoza SE. METFORMIN AS A POTENTIAL PHARMACOLOGIC INTERVENTION TO IMPROVE HEALTHSPAN. Innovation in Aging. 2024. doi:10.1093/geroni/igae098.0450.
BibTeX
@article{sara2024METFOR,
title = {METFORMIN AS A POTENTIAL PHARMACOLOGIC INTERVENTION TO IMPROVE HEALTHSPAN},
author = {Sara E Espinoza},
journal = {Innovation in Aging},
year = {2024},
doi = {10.1093/geroni/igae098.0450},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Innovation in Aging 2024
Open access · CC-BY
REPURPOSED FOR AGING
The Journals of Gerontology Series A 2023
Open access · CC0
Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop
Frontiers in Pharmacology 2021
Open access · CC-BY
Metformin: A Novel Weapon Against Inflammation
Journal of Education Health and Sport 2025
Open access · CC-BY
Metformin - An Antidiabetic Drug With Anti-aging, Cardioprotective And Potential Anti-cancer Properties
Pharmaceuticals 2023
Open access · CC-BY
Metformin: The Winding Path from Understanding Its Molecular Mechanisms to Proving Therapeutic Benefits in Neurodegenerative Disorders
IntechOpen eBooks 2023
Open access · CC-BY